FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078786472> ?p ?o ?g. }

• W2078786472 endingPage "3146" @default.
• W2078786472 startingPage "3136" @default.
• W2078786472 abstract "In this work, we aim to design and synthesize prodrugs of gatifloxacin targeting organic cation transporter (OCT), monocarboxylate transporter (MCT), and ATB (0, +) transporters and to identify a prodrug with enhanced delivery to the back of the eye. Dimethylamino-propyl, carboxy-propyl, and amino-propyl(2-methyl) derivatives of gatifloxacin (GFX), DMAP-GFX, CP-GFX, and APM-GFX, were designed and synthesized to target OCT, MCT, and ATB (0, +) transporters, respectively. An LC-MS method was developed to analyze drug and prodrug levels in various studies. Solubility and log D (pH 7.4) were measured for prodrugs and the parent drug. The permeability of the prodrugs was determined in the cornea, conjunctiva, and sclera-choroid-retinal pigment epitheluim (SCRPE) and compared with gatifloxacin using an Ussing chamber assembly. Permeability mechanisms were elucidated by determining the transport in the presence of transporter specific inhibitors. 1-Methyl-4-phenylpyridinium iodide (MPP+), nicotinic acid sodium salt, and α-methyl-dl-tryptophan were used to inhibit OCT, MCT, and ATB (0, +) transporters, respectively. A prodrug selected based on in vitro studies was administered as an eye drop to pigmented rabbits, and the delivery to various eye tissues including vitreous humor was compared with gatifloxacin dosing. DMAP-GFX exhibited 12.8-fold greater solubility than GFX. All prodrugs were more lipophilic, with the measured log D (pH 7.4) values ranging from 0.05 to 1.04, when compared to GFX (log D: −1.15). DMAP-GFX showed 1.4-, 1.8-, and 1.9-fold improvement in permeability across the cornea, conjunctiva, and SCRPE when compared to GFX. Moreover, it exhibited reduced permeability in the presence of MPP+ (competitive inhibitor of OCT), indicating OCT-mediated transport. CP-GFX showed 1.2-, 2.3-, and 2.5-fold improvement in permeability across the cornea, conjunctiva, and SCRPE, respectively. In the presence of nicotinic acid (competitive inhibitor of MCT), the permeability of CP-GFX was reduced across the conjunctiva. However, the cornea and SCRPE permeability of CP-GFX was not affected by nicotinic acid. APM-GFX did not show any improvement in permeability when compared to GFX across the cornea, conjunctiva, and SCRPE. Based on solubility and permeability, DMAP-GFX was selected for in vivo studies. DMAP-GFX showed 3.6- and 1.95-fold higher levels in vitreous humor and CRPE compared to that of GFX at 1 h after topical dosing. In vivo conversion of DMAP-GFX prodrug to GFX was quantified in tissues isolated at 1 h after dosing. The parent drug-to-prodrug ratio was 8, 70, 24, 21, 29, 13, 55, and 60% in the cornea, conjunctiva, iris-ciliary body, aqueous humor, sclera, CRPE, retina, and vitreous humor, respectively. In conclusion, DMAP-GFX prodrug enhanced solubility, log D, as well as OCT mediated delivery of gatifloxacin to the back of the eye." @default.
• W2078786472 created "2016-06-24" @default.
• W2078786472 creator A5024493838 @default.
• W2078786472 creator A5059534716 @default.
• W2078786472 creator A5075187158 @default.
• W2078786472 date "2012-10-11" @default.
• W2078786472 modified "2023-09-27" @default.
• W2078786472 title "Transporter Targeted Gatifloxacin Prodrugs: Synthesis, Permeability, and Topical Ocular Delivery" @default.
• W2078786472 cites W136232964 @default.
• W2078786472 cites W1529499411 @default.
• W2078786472 cites W1589822958 @default.
• W2078786472 cites W1897390225 @default.
• W2078786472 cites W1958525759 @default.
• W2078786472 cites W1965629903 @default.
• W2078786472 cites W1970780913 @default.
• W2078786472 cites W1971197733 @default.
• W2078786472 cites W1978576791 @default.
• W2078786472 cites W1983869986 @default.
• W2078786472 cites W1986318566 @default.
• W2078786472 cites W1997795542 @default.
• W2078786472 cites W1998564041 @default.
• W2078786472 cites W2007055518 @default.
• W2078786472 cites W2009692731 @default.
• W2078786472 cites W2011244391 @default.
• W2078786472 cites W2011854091 @default.
• W2078786472 cites W2013175282 @default.
• W2078786472 cites W2014621333 @default.
• W2078786472 cites W2015363453 @default.
• W2078786472 cites W2027086950 @default.
• W2078786472 cites W2037635296 @default.
• W2078786472 cites W2051011721 @default.
• W2078786472 cites W2054041974 @default.
• W2078786472 cites W2059477760 @default.
• W2078786472 cites W2068747778 @default.
• W2078786472 cites W2091450516 @default.
• W2078786472 cites W2096379223 @default.
• W2078786472 cites W2126348132 @default.
• W2078786472 cites W2135229007 @default.
• W2078786472 cites W2139334832 @default.
• W2078786472 cites W2145937688 @default.
• W2078786472 cites W2154883084 @default.
• W2078786472 cites W2155574040 @default.
• W2078786472 cites W2163966248 @default.
• W2078786472 cites W2170326611 @default.
• W2078786472 cites W230098639 @default.
• W2078786472 cites W2419665772 @default.
• W2078786472 cites W298827286 @default.
• W2078786472 cites W4242106333 @default.
• W2078786472 cites W4256289863 @default.
• W2078786472 cites W62207833 @default.
• W2078786472 doi "https://doi.org/10.1021/mp300245r" @default.
• W2078786472 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3926802" @default.
• W2078786472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23003105" @default.
• W2078786472 hasPublicationYear "2012" @default.
• W2078786472 type Work @default.
• W2078786472 sameAs 2078786472 @default.
• W2078786472 citedByCount "17" @default.
• W2078786472 countsByYear W20787864722013 @default.
• W2078786472 countsByYear W20787864722014 @default.
• W2078786472 countsByYear W20787864722015 @default.
• W2078786472 countsByYear W20787864722016 @default.
• W2078786472 countsByYear W20787864722018 @default.
• W2078786472 countsByYear W20787864722019 @default.
• W2078786472 countsByYear W20787864722020 @default.
• W2078786472 countsByYear W20787864722021 @default.
• W2078786472 countsByYear W20787864722022 @default.
• W2078786472 countsByYear W20787864722023 @default.
• W2078786472 crossrefType "journal-article" @default.
• W2078786472 hasAuthorship W2078786472A5024493838 @default.
• W2078786472 hasAuthorship W2078786472A5059534716 @default.
• W2078786472 hasAuthorship W2078786472A5075187158 @default.
• W2078786472 hasBestOaLocation W20787864722 @default.
• W2078786472 hasConcept C104317684 @default.
• W2078786472 hasConcept C108215921 @default.
• W2078786472 hasConcept C149011108 @default.
• W2078786472 hasConcept C185592680 @default.
• W2078786472 hasConcept C2777653605 @default.
• W2078786472 hasConcept C2778512257 @default.
• W2078786472 hasConcept C501593827 @default.
• W2078786472 hasConcept C55493867 @default.
• W2078786472 hasConcept C71924100 @default.
• W2078786472 hasConcept C98274493 @default.
• W2078786472 hasConceptScore W2078786472C104317684 @default.
• W2078786472 hasConceptScore W2078786472C108215921 @default.
• W2078786472 hasConceptScore W2078786472C149011108 @default.
• W2078786472 hasConceptScore W2078786472C185592680 @default.
• W2078786472 hasConceptScore W2078786472C2777653605 @default.
• W2078786472 hasConceptScore W2078786472C2778512257 @default.
• W2078786472 hasConceptScore W2078786472C501593827 @default.
• W2078786472 hasConceptScore W2078786472C55493867 @default.
• W2078786472 hasConceptScore W2078786472C71924100 @default.
• W2078786472 hasConceptScore W2078786472C98274493 @default.
• W2078786472 hasIssue "11" @default.
• W2078786472 hasLocation W20787864721 @default.
• W2078786472 hasLocation W20787864722 @default.
• W2078786472 hasLocation W20787864723 @default.
• W2078786472 hasLocation W20787864724 @default.
• W2078786472 hasOpenAccess W2078786472 @default.

• next